Abstract
This work is focused on SFTI-1, a member of the Bowman-Birk family of inhibitors. This 14 amino acid cyclic peptide exhibits several features i.e. compact rigidity, well-defined structure and small size that could result in a wide range of potential applications. Some examples of engineering of the specificity of this inhibitor along with structure - activity relationships will be discussed herein. Additionally, potential uses of STFI-1 and its analogs as pharmaceutical agents will be described.
Keywords: SFTI-1, inhibitor, serine proteinases, peptidomimetics, peptomers, analogs, pharmaceutical agents, cytotoxicity, trypsin, chymotrypsin
Current Pharmaceutical Design
Title: Sunflower Trypsin Inhibitor 1 as a Molecular Scaffold for Drug Discovery
Volume: 17 Issue: 38
Author(s): Adam Lesner, Anna Legowska, Magdalena Wysocka and Krzysztof Rolka
Affiliation:
Keywords: SFTI-1, inhibitor, serine proteinases, peptidomimetics, peptomers, analogs, pharmaceutical agents, cytotoxicity, trypsin, chymotrypsin
Abstract: This work is focused on SFTI-1, a member of the Bowman-Birk family of inhibitors. This 14 amino acid cyclic peptide exhibits several features i.e. compact rigidity, well-defined structure and small size that could result in a wide range of potential applications. Some examples of engineering of the specificity of this inhibitor along with structure - activity relationships will be discussed herein. Additionally, potential uses of STFI-1 and its analogs as pharmaceutical agents will be described.
Export Options
About this article
Cite this article as:
Lesner Adam, Legowska Anna, Wysocka Magdalena and Rolka Krzysztof, Sunflower Trypsin Inhibitor 1 as a Molecular Scaffold for Drug Discovery, Current Pharmaceutical Design 2011; 17 (38) . https://dx.doi.org/10.2174/138161211798999393
DOI https://dx.doi.org/10.2174/138161211798999393 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Histone Deacetylases: Anti-Angiogenic Targets in Cancer Therapy
Current Cancer Drug Targets Stress, Cardiovascular Diseases and Surgery-Induced Angiogenesis
Current Angiogenesis (Discontinued) Synthesis and Biological Evaluation of Licofelone Derivatives as Anticancer and Anti-inflammatory Agents
Letters in Drug Design & Discovery Polymer Nanoparticles - A Novel Strategy for Administration of Paclitaxel in Cancer Chemotherapy
Current Medicinal Chemistry Chemoprevention of Lung Pathologies by Dietary n-3 Polyunsaturated Fatty Acids
Current Medicinal Chemistry Recent Advancements in 1,4-Disubstituted 1H-1,2,3-Triazoles as Potential Anticancer Agents
Anti-Cancer Agents in Medicinal Chemistry Botanical Therapeutics (Part II): Antimicrobial and In Vitro Anticancer Activity against MCF7 Human Breast Cancer Cells of Chamomile, Parsley and Celery Alcoholic Extracts
Anti-Cancer Agents in Medicinal Chemistry Changing the Endocrine Dependence of Breast Cancer: Data and Hypotheses
Current Medicinal Chemistry Advances in Synergistic Combinations of Chinese Herbal Medicine for the Treatment of Cancer
Current Cancer Drug Targets Resveratrol and Its Analogues: Promising Antitumor Agents
Anti-Cancer Agents in Medicinal Chemistry A Single Center Phase II Study of Continuous Infusion of Low-dose 5- fluorouracil for Heavily Pretreated Patients With Metastatic Colorectal Cancer
Clinical Cancer Drugs The Role of Mitochondria in Cancer Induction, Progression and Changes in Metabolism
Mini-Reviews in Medicinal Chemistry Diethyldithiocarbamate complex with copper: the mechanism of action in cancer cells
Mini-Reviews in Medicinal Chemistry Targeting Indoleamine 2,3-dioxygenase (IDO) to Counteract Tumour- Induced ImmuneDysfunction: From Biochemistry to Clinical Development
Endocrine, Metabolic & Immune Disorders - Drug Targets Structure-activity Relationship Studies of New Marine Anticancer Agents and their Synthetic Analogues
Current Medicinal Chemistry Antidepressants and Sleep: Neurophysiology and Clinical Correlates
Current Psychiatry Reviews Redox Environment and its Meaning for Breast Cancer Cells Fate
Current Cancer Drug Targets Bortezomib as the First Proteasome Inhibitor Anticancer Drug: Current Status and Future Perspectives
Current Cancer Drug Targets Prostate-Specific G-Protein Coupled Receptor, an Emerging Biomarker Regulating Inflammation and Prostate Cancer Invasion
Current Molecular Medicine Involvement of Hypoxia-Inducible Factors in the Dysregulation of Oxygen Homeostasis in Sepsis
Cardiovascular & Hematological Disorders-Drug Targets